Plus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Receives Nasdaq Notice for Falling Below $1 Minimum Bid Requirement; Granted 180 Days to Regain Compliance
Plus Therapeutics, Inc. has announced that it received a notice from The Nasdaq Stock Market LLC regarding non-compliance with the minimum bid price requirement. The company's common stock has closed below $1.00 per share for 30 consecutive business days, failing to meet Nasdaq Listing Rule 5550(a)(2). This notice does not immediately affect the listing or trading of Plus Therapeutics' stock. The company has been given until November 12, 2025, to regain compliance by achieving a closing bid price of at least $1.00 per share for 10 consecutive business days. If unable to meet this deadline, Plus Therapeutics may qualify for an additional 180-day compliance period, provided it meets other Nasdaq listing requirements and plans to address the deficiency, potentially through a reverse stock split. The company is actively monitoring the situation and considering options to regain compliance, although there is no guarantee of success.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-074374), on May 19, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。